Physician profile
Wesley C Ray
NPI 1063403434
$5,938.12
in general payments reported to CMS, 2019-2025
28 companies · $1,207 in 2025
The $1,207 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $256 · 2021: $923 · 2022: $1,108 · 2023: $1,092 · 2024: $1,014 · 2025: $1,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,223 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,222.73 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,267.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $813.28 | 2019-2025 | |
| Pfizer INC. | $642.79 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $525.82 | 2020-2025 | Trintellix |
| Lilly USA, LLC | $475.91 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $466.97 | 2021-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $264.42 | 2021-2023 | Rexulti |
| Biohaven Pharmaceutical Holding Company Ltd. | $260.42 | 2022 | |
| Glaxosmithkline, LLC. | $243.09 | 2020-2025 | Arexvy, Trelegy Ellipta |
| Idorsia Pharmaceuticals US INC | $133.30 | 2022-2025 | Quviviq, Quviviq |
| Janssen Pharmaceuticals, INC | $109.63 | 2021-2024 | Xarelto, Spravato |
| Paratek Pharmaceuticals, INC. | $86.71 | 2023-2024 | Nuzyra |
| Phathom Pharmaceuticals, INC. | $79.63 | 2023-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.91 | 2024-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $66.99 | 2020-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $64.59 | 2023-2025 | Freestyle Libre 3 |
| Sunovion Pharmaceuticals INC. | $63.71 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $57.13 | 2024-2025 | Breztri, Airsupra |
| Urovant Sciences INC | $46.80 | 2022 | |
| Eisai INC. | $38.53 | 2021 | |
| Sumitomo Pharma America, INC. | $33.63 | 2023 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $25.30 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $23.28 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.00 | 2021 | |
| Merck Sharp & Dohme LLC | $15.32 | 2021 | |
| Antares Pharma, INC. | $14.31 | 2025 | Xyosted |
| Biodelivery Sciences International, INC. | $14.25 | 2021 | |
| Exact Sciences Corporation | $14.17 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.